Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Crofelemer
Therapeutic Area : Genetic Disease
Study Phase : IND Enabling
Recipient : Jaguar Health
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Mytesi (crofelemer) powder for oral solution inhibits both cAMP-stimulated CFTR chloride ion channel and the CaCC at the luminal membrane of enterocytes, which being investigated for the treatment of microvillus inclusion disease.
Brand Name : Mytesi
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 28, 2023
Lead Product(s) : Crofelemer
Therapeutic Area : Genetic Disease
Highest Development Status : IND Enabling
Recipient : Jaguar Health
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Crofelemer
Therapeutic Area : Gastroenterology
Study Phase : Phase I
Sponsor : SPRIM Global Investments
Deal Size : $58.8 million
Deal Type : Private Placement
Details : The company's initial focus is on clinical development and future registration in Europe of Mytesi (crofelemer) for two debilitating rare disease target indications: short bowel syndrome (SBS) and congenital diarrheal disorders (CDD) with intestinal fail...
Brand Name : Mytesi
Molecule Type : Small molecule
Upfront Cash : Undisclosed
February 09, 2023
Lead Product(s) : Crofelemer
Therapeutic Area : Gastroenterology
Highest Development Status : Phase I
Sponsor : SPRIM Global Investments
Deal Size : $58.8 million
Deal Type : Private Placement
LOOKING FOR A SUPPLIER?
Reset All
